PubMed

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.PMID: 16520473 [PubMed - indexed for MEDLINE]Related articlesFree article

Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.

[No authors listed]

Ann Intern Med. 2006 Mar 7;144(5):I29. No abstract available. PMID: 16520469 [PubMed - indexed for MEDLINE]Related articlesFree article

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.PMID: 17408535 [PubMed - indexed for MEDLINE]Related articlesFree article

Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.

Pignone M, Earnshaw S, Pletcher MJ, Tice JA.

Arch Intern Med. 2007 Feb 12;167(3):290-5.PMID: 17296886 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L.

Ann Intern Med. 2009 Feb 17;150(4):243-54.PMID: 19221376 [PubMed - indexed for MEDLINE]Related articlesFree article

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.

Schleinitz MD, Heidenreich PA.

Ann Intern Med. 2005 Feb 15;142(4):251-9.PMID: 15710958 [PubMed - indexed for MEDLINE]Related articlesFree article

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.

Blake GJ, Ridker PM, Kuntz KM.

Am J Med. 2003 Apr 15;114(6):485-94.PMID: 12727581 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.PMID: 10819699 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.

Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L.

Curr Med Res Opin. 2008 Jun;24(6):1823-32. Epub 2008 May 15.PMID: 18485270 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, Jackson PR.

Heart. 1999 Sep;82(3):325-32.PMID: 10455083 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.

Greving JP, Buskens E, Koffijberg H, Algra A.

Circulation. 2008 Jun 3;117(22):2875-83. Epub 2008 May 27.PMID: 18506010 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.

Ganz DA, Kuntz KM, Jacobson GA, Avorn J.

Ann Intern Med. 2000 May 16;132(10):780-7. Erratum in: Ann Intern Med 2002 Apr 16;136(8):635. PMID: 10819700 [PubMed - indexed for MEDLINE]Related articlesFree article

[Primary prevention of coronary heart disease? What is cost effective in the clinical practice?]

Kübler W.

Z Kardiol. 2005;94 Suppl 3:III/92-9. German. PMID: 16258799 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L.

N Engl J Med. 2002 Jun 6;346(23):1800-6.PMID: 12050341 [PubMed - indexed for MEDLINE]Related articlesFree article

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.

Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.

Circulation. 2007 May 8;115(18):2398-409. Epub 2007 Apr 23.PMID: 17452609 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

Hay JW, Sterling KL.

Pharmacoeconomics. 2005;23(2):133-41.PMID: 15748088 [PubMed - indexed for MEDLINE]Related articles

Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.

Fidan D, Unal B, Critchley J, Capewell S.

QJM. 2007 May;100(5):277-89. Epub 2007 Apr 21.PMID: 17449875 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

Simpson KN, Luo MP, Chumney EC, King MS, Brun S.

Clin Drug Investig. 2007;27(1):67-74.PMID: 17177581 [PubMed - indexed for MEDLINE]Related articles

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.

Lamotte M, Annemans L, Evers T, Kubin M.

Pharmacoeconomics. 2006;24(2):155-69.PMID: 16460136 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.

Gaziano TA, Opie LH, Weinstein MC.

Lancet. 2006 Aug 19;368(9536):679-86. Review.PMID: 16920473 [PubMed - indexed for MEDLINE]Related articlesFree article